Logo image of PMD

PSYCHEMEDICS CORP (PMD) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:PMD - US7443752057 - Common Stock

2.67 USD
-0.05 (-1.84%)
Last: 12/12/2024, 8:24:41 PM
2.36 USD
-0.31 (-11.61%)
After Hours: 12/12/2024, 8:24:41 PM

PMD Key Statistics, Chart & Performance

Key Statistics
Market Cap15.73M
Revenue(TTM)20.26M
Net Income(TTM)-3.00M
Shares5.89M
Float3.02M
52 Week High3.93
52 Week Low1.63
Yearly Dividend0.14
Dividend Yield12.67%
EPS(TTM)-0.51
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPO1987-01-22
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Providers & Services
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Services
PMD short term performance overview.The bars show the price performance of PMD in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 5 10 15

PMD long term performance overview.The bars show the price performance of PMD in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of PMD is 2.67 USD. In the past month the price increased by 13.86%. In the past year, price decreased by -10.4%.

PSYCHEMEDICS CORP / PMD Daily stock chart

PMD Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to PMD. When comparing the yearly performance of all stocks, PMD turns out to be only a medium performer in the overall market: it outperformed 54.69% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

PMD Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to PMD. While PMD seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

PMD Financial Highlights

Over the last trailing twelve months PMD reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 24.38% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -30.45%
ROE -54.99%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%74.79%
Sales Q2Q%-9.21%
EPS 1Y (TTM)24.38%
Revenue 1Y (TTM)-11.15%

PMD Forecast & Estimates


Analysts
Analysts100
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

PMD Ownership

Ownership
Inst Owners20.49%
Ins Owners12.5%
Short Float %N/A
Short RatioN/A

PMD Competitors/Peers

The largest stocks on the US markets in the "Health Care Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
CVS CVS HEALTH CORP 11.47 99.78B
CI THE CIGNA GROUP 9.58 72.72B
BTSGU BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 128.8 23.69B
LH LABCORP HOLDINGS INC 17.12 22.46B
DGX QUEST DIAGNOSTICS INC 19.41 21.08B
GH GUARDANT HEALTH INC N/A 14.45B
DVA DAVITA INC 11.35 7.39B
BTSG BRIGHTSPRING HEALTH SERVICES 38.43 7.07B
HIMS HIMS & HERS HEALTH INC 58.11 7.14B
CHE CHEMED CORP 20.54 6.40B
OPCH OPTION CARE HEALTH INC 24.18 5.72B
RDNT RADNET INC 186.82 5.48B

Related stock screener links

About PMD

Company Profile

PMD logo image Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. The company is headquartered in Acton, Massachusetts and currently employs 116 full-time employees. The firm provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The firm customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The firm markets its corporate drug testing services through its own sales force, distributors, and partners. The company markets its home drug testing service, PDT-90, through the Internet.

Company Info

PSYCHEMEDICS CORP

125 Nagog Park

Acton MASSACHUSETTS 01720 US

CEO: Raymond C. Kubacki

Employees: 116

PMD Company Website

PMD Investor Relations

Phone: 19782068220

PSYCHEMEDICS CORP / PMD FAQ

What does PMD do?

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. The company is headquartered in Acton, Massachusetts and currently employs 116 full-time employees. The firm provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The firm customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The firm markets its corporate drug testing services through its own sales force, distributors, and partners. The company markets its home drug testing service, PDT-90, through the Internet.


What is the stock price of PSYCHEMEDICS CORP today?

The current stock price of PMD is 2.67 USD. The price decreased by -1.84% in the last trading session.


Does PSYCHEMEDICS CORP pay dividends?

PSYCHEMEDICS CORP (PMD) has a dividend yield of 12.67%. The yearly dividend amount is currently 0.14.


What is the ChartMill technical and fundamental rating of PMD stock?

PMD has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What is the Price/Earnings (PE) ratio of PSYCHEMEDICS CORP (PMD)?

PSYCHEMEDICS CORP (PMD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.51).


How many employees does PSYCHEMEDICS CORP have?

PSYCHEMEDICS CORP (PMD) currently has 116 employees.


Can you provide the ownership details for PMD stock?

You can find the ownership structure of PSYCHEMEDICS CORP (PMD) on the Ownership tab.